Clinical Trial Update: Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating selpercatinib given before surgery for RET-altered thyroid cancers is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinoma
• Medullary Thyroid Carcinoma
• Papillary Thyroid Carcinoma
• Poorly Differentiated Thyroid Carcinoma
• Squamous Cell Carcinoma of the Thyroid
• Thyroid Cancer

Drugs mentioned

• Selpercatinib (selpercatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING